Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Oct 1, 2024
Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
BioCentury | Sep 26, 2024
Discovery & Translation
Science Spotlight: Targeted protein relocalization, rejuvenating aged eggs, and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 10, 2024
Product Development
Challenging King Keytruda
Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso aims to find out with ivonescimab
BioCentury | Jun 6, 2024
Discovery & Translation
Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more
BioCentury’s roundup of translational innovations
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | May 9, 2024
Management Tracks
Meyrick succeeding CMO Harris at radiopharma ITM
Plus: ALX hires Dillon and updates from Obsidian, YS and more
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Mar 30, 2024
Discovery & Translation
Science spotlight: Depleting an HSC pool improves immune function; plus new MS immune signatures and more
BioCentury’s roundup of translational innovations
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
Items per page:
1 - 10 of 221